Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Matasar · SciRah

Researcher profile · Semantic Scholar

M. Matasar

Share profile

M. Matasar — researcher profile on SciRah

h-index: 47
Works: 408
Citations: 8,688

Most-cited papers

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies
Laurie H. Sehn, N. Bartlett, M. Matasar, S. Schuster +17 more
2024Blood95 citations Open access
Semantic Scholar
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study
L. Budde, S. Assouline, L. Sehn, S. Schuster +16 more
2024Journal of Clinical Oncology57 citations Open access
Semantic Scholar
Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma
Franck Morschhauser, G. Salles, Laurie H. Sehn, Alex F. Herrera +33 more
2025Journal of Clinical Oncology37 citations Open access
Semantic Scholar
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study
Max S. Topp, M. Matasar, J. Allan, S. Ansell +15 more
2024Blood33 citations Open access
Semantic Scholar
Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes
G. Salles, F. Morschhauser, L. Sehn, A. Herrera +21 more
2024Blood23 citations
Semantic Scholar
Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL
A. Kittai, Ying Huang, Sarah Miller, John N. Allan +41 more
2025Blood Cancer Journal17 citations Open access
Semantic Scholar
CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma
P. Zinzani, Hua-Qing Wang, Ji-Feng Feng, Tae Min Kim +22 more
2024Blood Advances16 citations Open access
Semantic Scholar
Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas
Elise A. Chong, E. Penuel, E. Napier, Rachel K. Lundberg +16 more
2024Blood Advances15 citations
Semantic Scholar
Escalating Doses of AZD0486, a Novel CD19xCD3 T-Cell Engager, Result in High Complete Remissions with Rapid Clearance of Minimal Residual Disease in Patients with Relapsed/Refractory Follicular Lymphoma
Jing-Zhou Hou, R. Nair, Ryan W Jacobs, Tae Min Kim +16 more
2024Blood14 citations
Semantic Scholar
Phase 3 trial evaluating efficacy and safety of odronextamab plus CHOP vs rituximab plus CHOP in previously untreated diffuse large B-cell lymphoma (DLBCL; OLYMPIA-3).
M. Matasar, B. Turgut, B. Tessoulin, S. Guidez +14 more
2024Journal of Clinical Oncology11 citations
Semantic Scholar
ALPHA3, a Pivotal Phase 2 Study of First-Line Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma and Minimal Residual Disease after Response to Standard Therapy
J. Westin, A. Herrera, Ryan C. Lynch, J. Abramson +30 more
2024Blood11 citations
Semantic Scholar
Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, in Advanced Non-Hodgkin Lymphoma
P. Caimi, Scott F. Huntington, S. Landrette, S. Gough +6 more
2024Blood10 citations
Semantic Scholar
Mosunetuzumab with Response-Driven Lenalidomide Augmentation As First-Line Therapy for Symptomatic Follicular or Marginal Zone Lymphoma: Interim Analysis of a Multi-Center Phase 2 Study
A. Olszewski, M. Matasar, Scott F. Huntington, Thomas A. Ollila +12 more
2024Blood10 citations
Semantic Scholar
Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study
M. Shadman, N. Bartlett, M. Matasar, S. Schuster +16 more
2024Blood10 citations
Semantic Scholar
Impact of extranodal involvement at CAR T-cell therapy on outcomes in patients with relapsed or refractory large B-cell lymphoma—Results from a multicenter cohort study
Frédérique St-Pierre, Subodh Bhatta, P. Doukas, Madeline Jenkin +18 more
2025Blood Cancer Journal9 citations Open access
Semantic Scholar
Long-Term Efficacy and Safety of Odronextamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Pooled Analysis from the ELM-1 and ELM-2 Studies
J. Allan, J. Crombie, M. Matasar, Max S. Topp +10 more
2024Blood8 citations
Semantic Scholar
Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States
M. Matasar, J. Sánchez Álvarez, Hélène Parisé, Eric Zuk +4 more
2024Journal of Medical Economics8 citations Open access
Semantic Scholar
Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis
M. Cortese, M. Herr, N. Nair, J. Romancik +28 more
2024Blood8 citations
Semantic Scholar
Early clearance of circulating tumor DNA and association with odronextamab response in relapsed/refractory FL and DLBCL
Jon E. Arnason, M. Matasar, S. Luminari, D. Tucker +11 more
2025Blood Advances7 citations
Semantic Scholar
Treatment and outcomes of progression of disease post–CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis
Z. Epstein-Peterson, Anath C. Lionel, A. Joseph, Esther Drill +36 more
2025Blood Advances7 citations
Semantic Scholar
Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma
L. Budde, M. Matasar, L. Sehn, S. Assouline +15 more
2024Blood7 citations
Semantic Scholar
Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortium
M. Melody, Natalie S. Grover, Stephanie Franco, J. Romancik +26 more
2025Blood Advances5 citations Open access
Semantic Scholar
Pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter, Phase 2 trial
K. Patel, G. Shah, H. Schöder, N. Ganesan +25 more
2025Blood5 citations
Semantic Scholar
Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study
E. Budde, L. Sehn, M. Matasar, S. Schuster +16 more
2025Blood5 citations
Semantic Scholar
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP
K. Bantilan, Alexandra Smith, M. Maurer, Julie Teruya-Feldstein +14 more
2024Blood Advances5 citations Open access
Semantic Scholar
Survivorship preparedness and activation among survivors of lymphoma
Sharon L. Manne, S. Hudson, Denalee M. O'Malley, Katie A. Devine +5 more
2024Journal of cancer survivorship5 citations Open access
Semantic Scholar
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter transformation
K. Lewis, S. Assouline, R. Baker, N. Bartlett +13 more
2026Blood Advances4 citations Open access
Semantic Scholar
Odronextamab plus chemotherapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): First Results from part 1 of the Phase 3 Olympia-3 study
J. Michot, M. Yağcı, Katherine Kargus, H. Mohamed +5 more
2025Blood4 citations
Semantic Scholar
Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium
J. Wang, B. L. Ellsworth, M. Melody, Narandranath Epperla +26 more
2025Blood Advances4 citations Open access
Semantic Scholar
Perspectives of Lymphoma Survivors and Oncology Care Providers on Survivorship Care: A Qualitative Study
Jeanne M. Ferrante, Myneka Macenat, Jenna Howard, Nimi Patel +11 more
2025JCO Oncology Practice3 citations
Semantic Scholar
ALPHA3: A pivotal phase 2 study of first-line (1L) consolidation with cemacabtagene ansegedleucel (cema-cel) in patients (pts) with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy.
J. Westin, Gary L. Simmons, N. Bartlett, Houston E. Holmes +15 more
2025Journal of Clinical Oncology3 citations
Semantic Scholar
Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial
Raphael Steiner, L. Nikolaenko, R. Nair, V. Seshan +14 more
2025Blood Advances3 citations
Semantic Scholar
Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis
Z. Epstein-Peterson, Anath C. Lionel, A. Joseph, E. Drill +31 more
2024Blood3 citations
Semantic Scholar
Beyond maximum grade: long-term toxicity and survivorship in haematological malignancies.
T. Wästerlid, B. Valcárcel, Diana Presno, G. Stemmelin +7 more
2026The Lancet Haematology2 citations
Semantic Scholar
Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma
N. Khan, P. Dahi, F. Khimani, A. Shustov +20 more
2025Blood Advances2 citations
Semantic Scholar
Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies
Tae Min Kim, Jing-Zhou Hou, S. Gaballa, R. Nair +21 more
2025Blood2 citations
Semantic Scholar
MCL-339 GLOBRYTE: A Phase III, Open-label Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma
T. Phillips, M. Matasar, T. Eyre, Eva Evaé +7 more
2024Clinical Lymphoma, Myeloma & Leukemia2 citations
Semantic Scholar
A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma
A. Gurumurthi, K. Bantilan, P. Hamlin, Anita Kumar +8 more
2024Leukemia and Lymphoma2 citations
Semantic Scholar
Efficacy and Safety of Odronextamab Monotherapy in Patients (Pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR T-Cell Therapy: Primary Analysis from the ELM-1 Study
M. Matasar, Max S. Topp, J. Allan, S. Ansell +15 more
2024Blood2 citations
Semantic Scholar
Erratum to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
Z. Epstein-Peterson, E. Drill, U. Aypar, C. Batlevi +20 more
2024Haematologica2 citations Open access
Semantic Scholar
Efficacy, Toxicity, and Predictors of Outcomes with CD3-CD20 Bi-Specific Antibodies Post CAR T-Cell Failure for Aggressive B-Cell Lymphoma
M. Melody, Natalie S. Grover, Stephanie Franco, J. Romancik +26 more
2024Blood2 citations
Semantic Scholar
Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial
M. Matasar, Zhi-Ming Li, T. Vassilakopoulos, J. Sancho +15 more
2026Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Mosunetuzumab with response-driven lenalidomide augmentation achieves high response rates and immune reprogramming in untreated follicular and marginal zone lymphoma: A multicenter Phase 2 trial
A. Olszewski, M. Matasar, Scott Huntington, D. Bonal +13 more
2025Blood1 citations
Semantic Scholar
Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL)
Jing-Zhou Hou, Tae Min Kim, Seok-Goo Cho, S. Gaballa +20 more
2025Blood1 citations
Semantic Scholar
First-line consolidation with cemacabtagene ansegedleucel (cema-cel) in patients with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy: The pivotal, randomized, open‑label Phase 2 ALPHA3 study
John M. Burke, N. Bartlett, Gary L. Simmons, L. Fitzgerald +20 more
2025Blood1 citations
Semantic Scholar
Erratum: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.
Franck Morschhauser, Gilles Salles, Laurie H. Sehn, Alex F. Herrera +33 more
2025Journal of Clinical Oncology1 citations
Semantic Scholar
Treatment outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg-type in the rituximab era
G. Cassanello, E. Drill, A. Qiu, M. Ewalt +15 more
2025Blood Cancer Journal1 citations Open access
Semantic Scholar
Safety and efficacy of AZD0486, a CD19xCD3 T-cell engager, in relapsed or refractory diffuse large B-cell lymphoma.
Tae Min Kim, D. H. Yoon, S. Gaballa, Seok-Goo Cho +15 more
2025Journal of Clinical Oncology1 citations
Semantic Scholar
Immune biomarkers as predictors of response to mosunetuzumab in previously untreated follicular (FL) and marginal zone lymphoma (MZL).
C. Milrod, A. Chorzalska, John Morgan, M. Pardo +11 more
2025Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphoma
E. Joffe, Manik Uppal, Serena Zheng, K. Bantilan +22 more
2025Haematologica1 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Anita Kumar×9
Invite
Anita Kumar — researcher profile on SciRah
A. Zelenetz×9
Invite
A. Zelenetz — researcher profile on SciRah
Thomas A. Ollila×8
Invite
Thomas A. Ollila — researcher profile on SciRah
Michael C. Wei×7
Invite
Michael C. Wei — researcher profile on SciRah

×7

Invite

S. Yin — researcher profile on SciRah

Invite

N. Bartlett — researcher profile on SciRah

Don A. Stevens×7

Invite

Don A. Stevens — researcher profile on SciRah

L. Fitzgerald×7

Invite

L. Fitzgerald — researcher profile on SciRah

A. Pelcovits×7

Invite

A. Pelcovits — researcher profile on SciRah

Reem Karmali×7

Invite

Reem Karmali — researcher profile on SciRah

Invite

S. Schuster — researcher profile on SciRah

S. Assouline×6

Invite

S. Assouline — researcher profile on SciRah